Azurity Pharmaceuticals, Inc., a privately held company committed to delivering innovative, high-quality medicines, announced that the US Food and Drug Administration (FDA) has approved Xifyrm (meloxicam injection) an IV non-steroidal anti-inflammatory drug (NSAID) that offers once daily dosing.
• Xifyrm is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.
• Xifyrm provides a non-opioid analgesic in a 30mg/mL vial for IV bolus injection over 15 seconds.
• Because of delayed onset of analgesia, Xifyrm alone is not recommended for use when rapid onset of analgesia is required.
• “Xifyrm demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management,” said Ron Scarboro, CEO at Azurity Pharmaceuticals.
• “Xifyrm addresses an important clinical need, especially for patients requiring a non-opioid component to multimodal analgesia strategies.”
Xifyrm will be available in the coming weeks.
• Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients.
• Azurity’s global footprint is over 50 countries, with a diversified portfolio of 30+ marketed brands spanning ten dosage forms and ten key therapeutic areas.